Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with
Patented Augmenter of Cancer Immunotherapy NanoStilbene
OCEANSIDE, Calif., May 01, 2018 (GLOBE NEWSWIRE) — Via OTC PR Wire –Therapeutic Solutions International, Inc., (OTC Markets:TSOI) announced today signing of an agreement with the Pan Am Cancer Treatment Center covering production and clinical implementation of its patent pending StemVacs Platform in combination with our Patented immunological adjuvant NanoStilbene.
StemVacs is generated using dendritic cell progenitors isolated from patients, which are activated by a proprietary process which has previously been demonstrated to endow dendritic cells with the ability to produce “natural cytokines”, which kill cancer cells. NanoStilbene, a nanoparticle formulation of pterostilbene is covered for use in cancer immunotherapy under the Company’s issued U.S. Patent No.: 9,682,047. Pterostilbene is the active ingredient in the Company’s patented ProJuvenol product.
StemVacs is also subject of a filed Investigational New Drug Application (IND #17448) with the U.S. FDA. The IND seeks to establish safety and immune response of cancer, targeting a new personalized dendritic cell vaccine.
The Pan Am Cancer Treatment Center is a premier clinical research and treatment facility located in Tijuana, Mexico, which has been offering dendritic cell therapy for treatment of cancer patients. The current collaboration will leverage existing cellular therapy manufacturing expertise to develop and clinically apply, transfer factor pulsed autologous dendritic cells on the StemVacs Platform to patients.
“Having previously treated 10 patients with StemVacs in a proof-of-concept trial in collaboration with the Pan Am Cancer Treatment Center, we are very excited to expand the number of patients receiving this investigational immunotherapeutic approach,” said Timothy Dixon, President and Chief Executive Officer of TSOI. “Under Compassionate Use and Right to Try, we are able to offer this fee-for-service treatment not available anywhere else in the world and very pleased to do so and even more pleased that every patient treated will also be adding NanoStilbene to their personalized treatment protocol.”
“We are eager to offer this multi-protocol cancer immunotherapy to our patients, many of which who do not have any other treatment options available,” said Dr. Javier Lopez, Chief Executive Officer of the Pan American Cancer Treatment Center. “By working with internationally renowned experts, such as the Scientific Advisory Board of Therapeutic Solutions International, we will strive to provide the most advanced immunotherapy for our patients.”
“StemVacs is an immuno-oncology cellular therapy that programs the immune system to selectively attack malignant cells expressing the protein CTCFL, which acts as a “Master Orchestrator” of numerous genes needed for cancer to be cancer. Specifically, CTCFL is known to induce genes associated with cancer spreading, cancer mutating, and cancer becoming resistant to conventional therapies,” said Thomas E Ichim, Ph.D., Board Member of TSOI. “Recent studies have found an association between CTCFL and cancer stem cells, suggesting the possibility that StemVacs actively destroys the “root” of the tumor, thus potentially increasing the probability of efficacy. I am particularly excited about the combination with NanoStilbene, whose active ingredient has previously been reported to possess activity against breast cancer and prostate cancer, the two cancers that we are actively treating.”
About Therapeutic Solutions International, Inc.
The Company’s corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.
Therapeutic Solutions International, Inc.